Phospholipase A2 enzymes in metabolic and cardiovascular diseases

Current Opinion in Lipidology

Volumn 23, Issue 3, 2012, Pages 235-240

  Hui, David Y ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

atherosclerosis; diabetes; hyperlipidemia; inflammation; lysophospholipid; obesity

Indexed keywords

ARACHIDONIC ACID; CYTOKINE; LYSOPHOSPHOLIPID; PHOSPHOLIPASE A2; PHOSPHOLIPID; VERY LOW DENSITY LIPOPROTEIN; LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIET; ENZYME ANALYSIS; FATTY ACID OXIDATION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID ABSORPTION; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN SYNTHESIS; METABOLIC DISORDER; METABOLITE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; ANIMAL; ENZYMOLOGY; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INTRACELLULAR SPACE; LIPOPROTEINS; METABOLIC DISEASES; PHOSPHOLIPASES A2;

EID: 84861098161     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328351b439     Document Type: Review

References (33)

1. 2 in cardiovascular disease. Roles as biological effectors and biomarkers. Circulation 2010; 122:2183-2200.
2. Karabina S-A, Gora S, Atout R, Ninio E. Extracellular phospholipases in atherosclerosis. Biochimie 2010; 92:594-600.
3. Murakami M, Taketomi Y, Sato H, Yamamoto K. Secreted phospholipase A2 revisited. J Biochem 2011; 150:233-255.
4. Cathcart MK. Signal-activated phospholipase regulation of leukocyte chemotaxis. J Lipid Res 2009; 50:S231-S236.
5. Wilson SG, Adam G, Langdown M, et al. Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. Eur J Hum Genet 2006; 14:340-348.
6. Huggins KW, Boileau AC, Hui DY. Protection against diet-induced obesity and obesity-related insulin resistance in Group 1B PLA2-deficient mice. Am J Physiol 2002; 283:E994-E1001. (Pubitemid 35216958)
7. Cash JG, Kuhel DG, Goodin C, Hui DY. Pancreatic acinar cell-specific overexpression of group 1B phospholipase A2 exacerbates diet-induced obesity and insulin resistance in mice. Int J Obes 2011; 35:877-881.
8. Labonté ED, Kirby RJ, Schildmeyer NM, et al. Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes 2006; 55:935-941. (Pubitemid 44100167)
9. Labonté ED, Pfluger PT, Cash JG, et al. Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J 2010; 24:2516-2524.
10. Hollie NI, Hui DY. Group 1B phospholipase A2 deficiency protects against diet-induced hyperlipidemia in mice. J Lipid Res 2011; 52:2005-2011.
11. Robinson BS, Yao Z, Baisted DJ, Vance DE. Lysophosphatidylcholine metabolism and lipoprotein secretion by cultured rat hepatocytes deficient in choline. Biochem J 1989; 260:207-214. (Pubitemid 19139916)
12. Wanninger J, Neumeier M, Weigert J, et al. Metformin reduces cellular lysophosphatidylcholine and thereby may lower apolipoprotein B secretion in primary human hepatocytes. Biochim Biophys Acta 2008; 1781:321-325.
13. Hui DY, Cope MJ, Labonté ED, et al. The Phospholipase A2 inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br J Pharmacol 2009; 157:1263-1269.
14. Singer AG, Ghomashchi F, Le Calvez C, et al. Interfacial Kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 2002; 277:48535-48549. (Pubitemid 35470814)
15. Mounier CM, Ghomashchi F, Lindsay MR, et al. Arachidonic acid release from mammalian cells transfected with human group IIA and X secreted phospho-lipase A2 occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2. J Biol Chem 2004; 279:25024-25038. (Pubitemid 38756751)
16. BockKov VN, Kadl A, Huber J, et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002; 419:77-81. (Pubitemid 34987873)
17. Quarck R,De Geest B, Stengel D, etal. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipopro-tein E-deficient mice. Circulation 2001; 103:2495-2500. (Pubitemid 32493377)
18. 2 ameliorates inflammation and decreases atherosclerotic plaque formation in apoE-deficient mice. PLoS One 2011; 6:e23425.
19. Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009; 24:358-363.
20. Dohi T, Miyauchi K, Okazaki S, et al. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis 2011; 219:907-912.
21. Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospho-lipase A2 in the metabolic syndrome and diabetes. J Diabetes Complications 2006; 20:343-348. (Pubitemid 44633698)
22. Wilensky RL, Shi Y, Mohler ER, et al. Inhibition of lipoprotein- associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14:1059-1066.
23. Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Patents 2009; 20:1-18.
24. Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J 2011; 2:27-38.
25. Ivandic B, Castellani LW, Wang X-P, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999; 19:1284-1290. (Pubitemid 29227649)
26. Webb NR, Bostrom MA, Szilvassy SJ, et al. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:263-268. (Pubitemid 36231938)
27. 2 and small dense low density lipoproteins. Curr Opin Lipidol 2000; 11:465-471.
28. Tietge UJF, Pratico D, Ding T, et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res 2005; 46:1604-1614. (Pubitemid 41099327)
29. Rouault M, Le Calvez C, Boilard E, et al. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry 2007; 46:1647-1662.
30. Bobryshev YV, Crozier JA, Lord RS, et al. Expression of secretory group II phospholipase A2 by CD1a positive cells in human atherosclerotic plaques. Atherosclerosis 1996; 127:283-285. (Pubitemid 27045842)
31. Jaulmes A, Thierry S, Janvier B, et al. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1β. FASEB J 2006; 20:1727-1729.
32. Dutour A, Achard V, Sell H, et al. Secretory type II phospholipase A2 Is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease. J Clin Endocrinol Metab 2010; 95:963-967.
33. Anwar K, Voloshyna I, Littlefield MJ, et al. COX2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell forma tion in THP-1 cells. Lipids 2011; 46:131-142.